Lung Cancer | Oncology Today with Dr Neil Love: NSCLC with EGFR Exon 20 Insertion Mutations

Featuring an interview with Dr Gregory Riely, including the following topics: EGFR exon 20 insertions in non-small cell lung cancer (NSCLC) (0:00) Antitumor activity, mechanism of action and tolerability of mobocertinib for patients with NSCLC and EGFR exon 20 mutations (4:59) Antitumor activity and tolerability of the EGFR-MET bispecific antibody amivantamab (11:05) Considerations for using real-world data to create synthetic control arms for clinical trials (17:48) Novel investigational agents for and future management of NSCLC with EGFR exon 20 insertions (23:48) CME information and select publications